• Fri frakt över 249 kr
  • •
  • Snabba leveranser
  • •
  • Billiga böcker
Kundservice

Du är på sajten för privatpersoner.

Företag, bibliotek eller offentlig verksamhet?

Du handlar på classic.bokus.com, där alla dina funktioner finns intakta.
Till classic.bokus.com
Bokus logotyp. Gå till startsidan.
  • Erbjudanden
  • Nyheter
  • Student
  • Topplistor
  • Barn & ungdom
  • Bokus Play
  • E-böcker
  • Pocketböcker
  • Spel & pussel

10% rabatt på allt med kod: NYSTART10 →

Sidfot

Mina sidor

    Hjälp

    • Kundservice
    • Vanliga frågor och svar
    • Frakt och leverans
    • Retur vid ångerrätt
    • Reklamera vara
    • Betalning
    • Köpvillkor
    • Allmänna villkor
    • Information om webbplatsens tillgänglighet

    Om Bokus

    • Om oss
    • Pressrum
    • För studenter
    • För företag
    • För bibliotek och offentlig verksamhet
    • För leverantörer
    • Hållbarhet

    Populärt

    • Aktuella erbjudanden
    • Presentkort
    • Studentlitteratur
    • Nya böcker
    • Topplistor
    • Signerade böcker
    • Engelska böcker

    Inspiration

    • Boktips
    • BookTok
    • Populära bokserier
    • Barnbokskaraktärer
    • Populära författare
    Logotyp för Bokus
    Följ oss på Facebook (extern länk)Följ oss på Instagram (extern länk)Följ oss på YouTube (extern länk)Följ oss på TikTok (extern länk)
    bokus @ CookiesAnpassa cookiesIntegritetspolicyKöpvillkor
    Till Citymail hemsida (extern länk)Till Budbee hemsida (extern länk)Till Postnord hemsida (extern länk)Till Schenker hemsida (extern länk)Till Early Bird hemsida (extern länk)Till Walleys hemsida (extern länk)
    1. Medicin
    2. Klinisk medicin och internmedicin
    3. Sjukdomar och rubbningar
    4. Onkologi

    Patient Surveillance After Cancer Treatment

    AvFrank E Johnson,Yoshihiko Maehara

    Inbunden, Engelska, 2013

    Del i serien Current Clinical Oncology

    2 230 kr

    Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

    Beskrivning

    Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer.The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients.This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today’s practicing oncologist.

    Produktinformation

    • Utgivningsdatum:2013-03-08
    • Mått:210 x 279 x 35 mm
    • Vikt:1 602 g
    • Format:Inbunden
    • Språk:Engelska
    • Serie:Current Clinical Oncology
    • Antal sidor:538
    • Upplaga:2012
    • Förlag:Humana Press Inc.
    • ISBN:9781603279680

    Utforska kategorier

    • Onkologi inom Medicin
    • Onkologisk kirurgi inom Medicin

    Mer om författaren

    Dr. Frank E. Johnson, MD

    Recensioner i media

    From the reviews: "This book discusses surveillance strategies for patients completing curative-intent primary treatment for cancer. ... Members of the oncology treatment team as well as primary care health professionals who provide post-treatment follow-up survivorship care will benefit from this informative, disease-specific resource. ... This is an extremely valuable and useful compilation of cancer site-specific surveillance guidelines for follow-up of asymptomatic patients who have completed primary treatment with curative intent." (Judith G. Abramson, Doody's Book Reviews, September, 2013) "Patient Surveillance After Cancer Treatment is a well-written, well-organized reference designed to speak to any practicing oncologist or primary care provider that follows cancer patients after treatment for curative intent. ... This is a great text and reference to any clinically practicing oncologist, primary care provider, survivorship program, and training physician of any level. Patient Surveillance After Cancer Treatment will continue to prove itself useful and will be readily available in our library." (Nima Nabavizadeh and David Elliott, Journal of Radiation Oncology, Vol. 2 (3), September, 2013)

    Innehållsförteckning

    • 1. Overview.- 2. Introduction to Cancer Surveillance Strategies.- 3. Using Decision Analysis to Model Cancer Surveillance.- 4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment.- 5. Upper Aerodigestive Tract Carcinoma.- 6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe.- 7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan.- 8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada.- 9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma.- 10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia.- 11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan.- 12. Lung Carcinoma.- 13. Lung Carcinoma Surveillance Counterpoint: Australia.- 14. Lung Carcinoma Surveillance Counterpoint: Japan.- 15. Lung Carcinoma Surveillance Counterpoint: Canada.- 16. Esophagus Carcinoma.- 17. Esophagus Carcinoma Surveillance Counterpoint: Australia.- 18. Esophagus Carcinoma Surveillance Counterpoint: Japan.- 19. Stomach.- 20. Stomach Carcinoma Surveillance Counterpoint: USA.- 21. Stomach Carcinoma Surveillance Counterpoint: Japan.- 22. Pancreatic Adenocarcinoma.- 23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA.- 24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe.- 25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan.- 26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada.- 27. Liver and Biliary Tract Carcinoma.- 28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe.- 29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia.- 30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan.- 31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada.- 32. Colon and Rectum Carcinoma.- 33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA.- 34. Colon and RectumCarcinoma Surveillance Counterpoint: Australia.- 35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan.- 36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada.- 37. Anal Carcinoma.- 38. Anal Carcinoma Surveillance Counterpoint: USA.- 39. Anal Carcinoma Surveillance Counterpoint: Australia.- 40. Anal Carcinoma Surveillance Counterpoint: Japan.- 41. Anal Carcinoma Surveillance Counterpoint: Canada.- 42. Soft Tissue Sarcoma.- 43. Soft Tissue Sarcoma Surveillance Counterpoint: USA.- 44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan.- 45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada.- 46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma.- 47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan.- 48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada.- 49. Cutaneous Melanoma.- 50. Cutaneous Melanoma Surveillance Counterpoint: USA.- 51. Cutaneous Melanoma Surveillance Counterpoint: Australia.- 52. Cutaneous Melanoma Surveillance Counterpoint: Japan.- 53. Breast Carcinoma.- 54. Breast Carcinoma Surveillance Counterpoint: USA.- 55. Breast Carcinoma Surveillance Counterpoint: Europe.- 56. Breast Carcinoma Surveillance Counterpoint: Australia.- 57. Breast Carcinoma Surveillance Counterpoint: Japan.- 58. Endometrial Carcinoma.- 59. Endometrial Cancer Surveillance Counterpoint: USA.- 60. Endometrial Cancer Surveillance Counterpoint: USA.- 61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan.- 62. Endometrial Carcinoma Surveillance Counterpoint: Canada.- 63. Cervical Carcinoma.- 64. Cervical Carcinoma Surveillance Counterpoint: USA.- 65. Cervical Carcinoma Surveillance Counterpoint: Japan.- 66. Cervical Carcinoma Surveillance Counterpoint: Canada.- 67. Vaginal and Vulvar Carcinoma.- 68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan.- 69. Ovarian Carcinoma.- 70. Ovarian Carcinoma Surveillance Counterpoint:USA.- 71. Ovarian Cancer Surveillance Counterpoint: Europe.- 72. Ovarian Cancer Surveillance Counterpoint: Japan.- 73. Renal Carcinoma.- 74. Renal Carcinoma Surveillance Counterpoint: Europe.- 75. Renal Carcinoma Surveillance Counterpoint: Japan.- 76. Renal Carcinoma Surveillance Counterpoint: Canada.- 77. Urinary Bladder Carcinoma.- 78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan.- 79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada.- 80. Prostate Carcinoma.- 81. Prostate Carcinoma Surveillance Counterpoint: USA.- 82. Prostate Carcinoma Surveillance Counterpoint: USA.- 83. Prostate Carcinoma Surveillance Counterpoint: Europe.- 84. Prostate Carcinoma Surveillance Counterpoint: Japan.- 85. Prostate Carcinoma Surveillance Counterpoint: Canada.- 86. Testicle Carcinoma.- 87. Testicle Carcinoma Surveillance Counterpoint: USA.- 88. Testicle Carcinoma Surveillance Counterpoint: Australia.- 89. Testicle Carcinoma Surveillance Counterpoint: Japan.- 90. Lymphoma.- 91. Lymphoma Surveillance Counterpoint: USA.- 92. Lymphoma Surveillance Counterpoint: Japan.- 93. Lymphoma (Following Autologous Stem Cell Transplant).- 94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan.- 95. Leukemia.- 96. Leukemia Surveillance Counterpoint: USA.- 97. Leukemia Surveillance Counterpoint: Japan.- 98. Multiple Myeloma.- 99. Multiple Myeloma Surveillance Counterpoint: USA.- 100. Multiple Myeloma Surveillance Counterpoint: Australia.- 101. Multiple Myeloma Surveillance Counterpoint: Japan.- 102. Multiple Myeloma Surveillance Counterpoint: Canada.- 103. Glioma of the Central Nervous System.- 104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe.- 105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia.- 106. Glioma of the Central Nervous System Surveillance Counterpoint:Japan.